Rationale and design of the vericiguat in vasospastic angina (ViVA) trial: A double-blind placebo-controlled randomized cross-over study.
Am Heart JApr 23, 2026 (epub)
Clinical ResearchCardiology
Hanae F Namba, Elize A M de Jong, Coen K M Boerhout et al.
✦ AI-curated · Sources linked
In 30 seconds
The Vericiguat in Vasospastic Angina (ViVA) trial is a double-blind, placebo-controlled randomized cross-over study investigating the effects of vericiguat on patients with angina and no obstructive coronary arteries (ANOCA). The study aims to evaluate vericiguat's impact on endothelial function, microvascular vasodilator responses, angina frequency, and quality of life in 50 patients.
Key findings
- The trial will include 50 patients with ANOCA.
- Patients will be randomized in a 1:1 ratio to receive either placebo or vericiguat first.
- Vericiguat is hypothesized to reduce coronary spasm episodes.
Why it matters
Understanding the effects of vericiguat on coronary vasospasm could provide new therapeutic options for patients with ANOCA, a condition often challenging to manage due to the absence of obstructive coronary disease.